This session will provide a foundation for the basic pathophysiology, etiology, and diagnosis of hematologic disorders including immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC). The critical role of the pharmacist in the treatment of each disease state will be elucidated. The context of these disorders in the setting of COVID-19 and vaccine-associated sequelae will be explored. Pharmacists and pharmacy learners who do not have expertise in Hematology practice will gain confidence in their diagnosis and management skills. Additionally, this session is meant to offer late-breaking updates in the treatment of hematologic disorders for Hematology/Oncology pharmacists in practice. The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCOP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on December 14, 2022, at www.accp.com/myaccount to anyone who has purchased access to the BCOP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 18, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 12, 2023.